Navigation Links
Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Date:4/20/2009

- Anthim Dramatically Improves Survival in Animals with Clinical Symptoms of Anthrax disease -

PINE BROOK, N.J., April 20 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced the initiation of a second Phase I human safety trial of Anthim(TM), a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO)

The Phase I dose-escalation trial is planned to enroll 45 healthy volunteers and is designed to expand the human safety database. Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented, "We are extremely pleased with the success of our development program for Anthim. Our drug consistently demonstrates remarkable efficacy in treating anthrax infection in animal models and is a strong candidate for addition to the Strategic National Stockpile."

The Company also reported the results of a previously conducted animal efficacy study. A single dose of Anthim provided a significant survival benefit (up to 94 percent survival in treated rabbits vs. 0 percent in controls) when administered to symptomatic rabbits. These results are consistent with several previous rabbit and primate studies that Elusys has conducted and show the dramatic protective effect of Anthim. Dr. Leslie Casey, Vice President of Research, commented, "Anthim has shown significant life-saving potential even when given in a single dose to symptomatic animals many hours after anthrax exposure. In earlier animal studies, Anthim provided 100 percent pro
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Another LNA-based RNA Inhibitor Enters Clinical Trials
7. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
8. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... , , PISCATAWAY, N.J., Dec. 3 /PRNew... Bulletin Board: MLSS), the recognized leader in a...at it had entered into a joint venture with China ...arm") and Yichang Humanwell Pharmaceutical Co. Ltd...hina (the "PRC"), to develop orthopedic and epidur...
(Date:12/3/2009)... , , MAPLE GROVE, Minn., Dec. 3 /PRNe...nnounced the next phase of its strategic plan for ...(extended release topiramate), an internally devel...5 is being developed with Upsher-Smith,s proprieta...II clinical trial in early 2010 for the adjunctive...
(Date:12/3/2009)... , , ROCHESTER, N.Y., Dec. 3 /PRNewswire-F...), a leading provider of quantitative imaging for ...itled "System and Method for 4D Reconstruction and...n. ,, VirtualScopics, Vice President of Technol...ated, "We are pleased that Japan has recognized th...
Breaking Medicine Technology:Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 2Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 3Upsher-Smith Announces Milestone in Development of CNS Strategy 2VirtualScopics Receives Issuance in Japan of Prominent Patent 2VirtualScopics Receives Issuance in Japan of Prominent Patent 3HealthFitness President Gregg O Lehman Named to DMAA Board of Directors 58047 1HealthFitness President Gregg O Lehman Named to DMAA Board of Directors 58047 2Small Steps May Speed Recovery in ICU Patients 58045 1Small Steps May Speed Recovery in ICU Patients 58045 2Hormone Therapy for Prostate Cancer Raises Heart Risks 58043 1Hormone Therapy for Prostate Cancer Raises Heart Risks 58043 2
...mprovement in Personal and Social,Performance,...re/ --,Longer-term treatment with INVEGA(TM) (pa... daily oral medication for,schizophrenia, helped...s and maintain their improvements in personal and ...om a large, open label, international,clinical t...
...WIRE)--Mar 30, 2007 - NEOPHARM, Inc.,(Nasdaq: NEOL...trial in second-line metastatic colorectal cancer ...the active metabolite of irinotecan,(Camptosar(R))...,completion of treatment of the first 21 patients ...not achieve the primary tumor,response endpoint. N...
Other Medicine Technology:Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 2Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 3Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 4Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 5Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 6NeoPharm Provides Update on LE-SN38 Program 2
(Date:12/3/2009)... Calif., Dec. 3 The Boa...al Studies unanimously voted to elect three new m..., Fred Dotzler is co-founder and Managing Direc...vo is investing $650 million from three funds in e...ies. Dotzler founded Medicus Venture Partners in 1...
(Date:12/3/2009)...A, Calif., Dec. 3 For California,s...sk of disability remains one of the most significa...ll being, but also their business,s viability. ,...en their toll, owners of small businesses are reco...y net with enhanced disability coverage," said Mi...
(Date:12/3/2009)... Fla., Dec. 3 If you have seen "Su... for a stunning look at the other side of the dini... screen her feature documentary, "Supercharge Me! ...ember 8th, 5 p.m. at Sever Hall, Harvard Yard. The...College Tour. The film will be followed by a lectu...
(Date:12/3/2009)..., Pa., Dec. 3 Southern Tier Health...are Inc. (ICW), a global leader in eHealth technol...nents for its Health Information Exchange (HIE). ...ndex (EMPI), Enterprise Master Provider Registry (...ties, 470,000 residents, 8 hospitals, and over 800...
(Date:12/3/2009)... Harmful procedures on young women caused by outd...ch sues FDA on December 11 for blocking new techno...EB) December 2, 2009 -- Now the American College ...hat the invasive cancer workup procedure, also kno...nnecessary to some women who have received the pro...
Breaking Medicine News(10 mins):Health News:Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4Health News:Jenna Norwood to Present Award-Winning Documentary & Lecture at Harvard University 2Health News:Southern Tier HealthLink NY Selects InterComponentWare to Deliver Core Components of HIE 2Health News:Harmful Procedures on Young Women Caused by Outdated HPV test, not by Pap Test 2
...n of Leading Calcium Brand Enriches Consumer Care ...oduct Portfolio, MORRISTOWN, N.J., Oct. 5 Bayer ... Care Division has received regulatory,approvals n...Mission Pharmacal was closed yesterday evening at ...
...POLIS, Oct. 5 Eli Lilly and Company,announced tod... U.S. Food,and Drug Administration (FDA), the comp...mbyax(R) (olanzapine and fluoxetine HCl) U.S. prod...ed pooled analyses of Lilly,s,clinical trial data ...
..., Oct. 5 Cell Therapeutics, Inc. (CTI),(Nasdaq: ...hnology Industry,Organization (BIO) Investor Forum...-11, 2007, at the Palace Hotel in,San Francisco. C...tation. The webcast can be accessed at, http://www...
...AN FRANCISCO, Calif., Oct. 5 Anesiva,Inc. (Nasdaq... the company,s,chief executive officer, will prese...IO InvestorForum 2007" on Thursday, October 11, 20... Investors page, and click on,Events. Please conne...
...Oct. 5 Any well-informed parent knows about the,F...ith cold & flu season,upon us, parents scramble to...gestion. Nosefrida nasal aspirator -- a Swedish pr...ar medicines such as Dimetapp and Triaminic,rarely...
...ent, Health, NGOs, Sports, Academic, and Business ...l-being of Individuals with Intellectual ..., Oct. 5 /Xinhua-PRNewswire-USNewswire/ -- Leaders...pecial Olympics World Summer Games in Shanghai, Ch...
Other Medicine News:Health News:Bayer HealthCare Cleared to Acquire Citracal(R) 2Health News:Bayer HealthCare Cleared to Acquire Citracal(R) 3Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 2Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 3Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 4Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 5Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 6Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 7Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 8Health News:Nosefrida Nasal Aspirator - A Parent's Alternative to Medicines on the Verge of FDA Ban 2Health News:Global Leaders Converge for Special Olympics Global Policy Summit 2Health News:Global Leaders Converge for Special Olympics Global Policy Summit 3Health News:Global Leaders Converge for Special Olympics Global Policy Summit 4
Premier Thumb Spica
FREEDOM® Memory Thumb Spica
QualCraft™ Gamekeeper Thumb Stabilizer
...dom® CMC ThumbFit™ reduces joint instabi...ofile splint is remarkably comfortable and easy fo... CHT and Robert V. Sypher Jr., MD, FAAOS, develope...plaints of discomfort and impaired hand function f...
Medicine Products: